- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
March 25, 2024Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
ANDA Litigation Settlements
Fall 2017
| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| Vivus Inc. v. Actavis Labs. FL Inc., 14-3786 (D.N.J.) | Qsymia® (phentermine / topiramate) | 7,056,890
7,553,818 7,659,256 7,674,776 8,580,298 8,580,299 |
Actavis to start selling its generic product on Dec. 1, 2024, or earlier “under certain circumstances.” Should Actavis begin selling a generic before its 2024 deadline, Vivus will collect royalties. |
| Eli Lilly and Co. v. Actavis Labs. UT Inc., 16-1119 (E.D. Va.) | Cialis® (tadalafil tablets) | 6,943,166 | Eli Lilly retains exclusivity over Cialis market until at least Sept. 27, 2018. Eli Lilly and generic defendants entered into a royalty-bearing license agreement. |
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) | OxyContin® (oxycodone HCl extended-release tablets) | 9,073,933 | N/A |
| Amgen v. Apotex Inc., 16-0926 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| Amgen Inc. v. Micro Labs Ltd., 16-0854 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) | Byetta® (exenatide for injection) | 6,872,700 6,902,744 |
N/A |
| AstraZeneca AB v. Torrent Pharma Inc., 15-3375 (D.N.J.) | Daliresp® (roflumilast tablets) | 5,712,298 8,536,206 8,604,064 8,618,142 |
N/A |
GENERICally Speaking Fall 2017
Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.